Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1657-1661

  Yoshimatsu, Kazuhiko ^a   Yokomizo, Hajime ^a   Fujimoto, Takashi ^a   Umehara, Arihiro ^a   Otani, Taisuke ^a   Matsumoto, Atsuo ^a   Osawa, Gakuji ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination chemotherapy; CPT 11; Low dose chemotherapy; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FLUSHING; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PILOT STUDY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PILOT PROJECTS; SURVIVAL; TEGAFUR;

EID: 34249309237     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kelly H and Goldberg RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23: 4553-4560, 2005.
2. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
3. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
4. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N and Shirasaka T: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39: 205-211, 1997.
5. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000.
6. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H and Satoh A: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100: 2355-2361, 2004.
7. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB and Fumoleau P: EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653, 2003.
8. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997.
9. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V and de Gramont A: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343-1347, 1999.
10. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
11. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17: 968-673, 2006.
12. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A and Buzzoni R: Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100: 279-287, 2004.
13. Patt YZ, Leibmann J, Diamandidis D et al: Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. (Abstract) J Clin Oncol 22: 271, 2004.
14. Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C and Cunningham D: A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 14: 1264-1269, 2003.
15. Yamada Y, Yasui H, Goto A, Arai T, Ura T, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol 8: 374-380, 2003.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
17. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 3: 176-181, 2003.
18. Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A and Muggia F: Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 21: 2703-2707, 2003.
19. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
20. Cheeseman S, Joel S, Chester J, Wilson G, Dent JT, Richards FJ and Seymour MT: A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87: 393-399, 2002.
21. Mokyr MB and Dray S: Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest 5: 31-38, 1987.
22. Mitchell MS and DeConti RC: Immunosuppression by 5-fluorouracil. Cancer 26: 884-889, 1970.
23. Ulrichs K, Yu MY, Duncker D and Muller-Ruchholtz W: Immunosuppression by cytostatic drugs? Behring Inst Mitt 74: 239-249, 1984.
24. Nio Y, Imai S, Shiraishi T, Ohgaki K and Tobe T: Lymphocytes anticancer chemosensitivity testing in vitro - an approach to predict immunosuppressive effect of anticancer agents. J Clin Lab Immunol 29: 141-145, 1989.
25. Lee M, Yea SS and Jeon YJ: Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipoplysaccharide stimulation. Int J Immunopaharcol 22: 615-621, 2000.
26. Takahashi Y and Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87: 1262-1263, 1995.
27. Ishibashi K, Yoshimatsu K, Yokomizo H, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Katsube T, Naritaka Y and Ogawa K: Low-dose leucovorin and 5-Fluorouracil for unresectable multiple liver metastasis from colorectal cancer. Anticancer Res 25: 4747-4752, 2005.
28. Yoshimatsu K, Kato H, Ishibashi K, Hashimoto M, Umehara A, Yokomizo H, Yoshida K, Fujimoto T, Iwasaki K and Ogawa K: Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother Pharmacol 52: 465-468, 2003.